Question? Call us
212-363-7500Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Capricor Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: Capricor issued a press release on May 5, 2025, announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold an advisory committee meeting" in connection with the BLA. Following this news, Capricor's stock price fell over 29% on May 6, 2025.
In order to be eligible to join the CAPR class action lawsuit, you must have incurred a loss on shares of Capricor Therapeutics, Inc. purchased during the class period listed above.
TOP